Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study to Evaluate the Safety, Tolerability and Biodistribution Characteristics of 177 Lu FAP VG11 Injection in Patients With Advanced Solid Tumours

NCT07808177 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT07808177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07808177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study to Evaluate the Safety, Tolerability and Biodistribution Characteristics of 177 Lu FAP VG11 Injection in Patients With Advanced Solid Tumours
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 1
Overall status
Recruiting
Start date
June 17, 2026
Completion date
May 6, 2029
Enrollment
7 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibroblast activation protein (fap)-positive advanced solid tumours